Long COVID, C diff, Candida auris: This Week's Infectious Disease Stories to Watch

Article

Stay informed about the long-term effects of COVID-19, prevention strategies for recurrent C diff, and the emerging threat of drug-resistant Candida auris.

Recent Videos
A panel of 5 experts on C. difficile infections
A panel of 5 experts on C. difficile infections
A panel of 5 experts on C. difficile infections
A panel of 5 experts on C. difficile infections
A panel of 5 experts on C. difficile infections
A panel of 5 experts on C. difficile infections
A panel of 5 experts on C. difficile infections
A panel of 5 experts on C. difficile infections
Related Content
A Clinician’s Perspective on Rebyota for Recurrent C Diff Treatment

A Clinician’s Perspective on Rebyota for Recurrent C Diff Treatment

John Parkinson;Timothy Ritter, MD
October 23rd 2024
Article
C difficile, Antimicrobials, and the Patients Most Affected

C difficile, Antimicrobials, and the Patients Most Affected

Nina Cosdon
November 23rd 2022
Podcast
Real World Study of Recurrent Clostridioides difficile Therapy Demonstrates Efficacy, Safety

Real World Study of Recurrent Clostridioides difficile Therapy Demonstrates Efficacy, Safety

John Parkinson
October 16th 2024
Article
New Insights into Clostridioides difficile Infection and Vaccine Development

New Insights into Clostridioides difficile Infection and Vaccine Development

Sophia Abene
October 14th 2024
Article
Top 5 Infectious Disease News Stories Week of September 27-October 4

Top 5 Infectious Disease News Stories Week of September 27-October 4

Sophia Abene
October 5th 2024
Article
C diff Treatment: Fidaxomicin's Rise as The Preferred Therapy Post-IDSA Guidelines

C diff Treatment: Fidaxomicin's Rise as The Preferred Therapy Post-IDSA Guidelines

Sophia Abene
October 3rd 2024
Article
© 2024 MJH Life Sciences

All rights reserved.